ABSTRACT
Objective To explore the molecular processes associated with cellular regulatory programs in patients with COVID-19, including gene activation or repression mediated by epigenetic mechanisms. We hypothesized that a comprehensive gene expression profiling of nasopharyngeal epithelial cells might expand understanding of the pathogenic mechanisms of severe COVID-19.
Methods We used single-cell RNA sequencing (scRNAseq) profiling of ciliated cells (n = 12725) from healthy controls (SARS-CoV-2 negative n =13) and patients with mild/moderate (n =13) and severe (n =14) COVID-19. ScRNAseq data at the patient level were used to perform gene set and pathway enrichment analyses. We prioritized candidate miRNA-target interactions and epigenetic mechanisms.
Results Pathways linked to mitochondrial function, misfolded proteins, and membrane permeability were upregulated in patients with mild/moderate disease compared to healthy controls. Besides, we noted that compared to mild/moderate disease, cells derived from severe COVID-19 patients had downregulation of sub-networks associated with epigenetic mechanisms, including DNA and histone H3K4 methylation and chromatin remodeling regulation. We found 11-ranked miRNAs that may explain miRNA-dependent regulation of histone methylation, some of which share seed sequences with SARS-CoV-2 miRNAs.
Conclusion Our results may provide novel insights into the epigenetic mechanisms mediating the clinical course of SARS-CoV-2 infection.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was partially funded by: Agencia Nacional de Promocion Cientifica y Tecnologica (Argentina)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study involves only openly available human data, reported in a previous paper, which can be obtained from: https://singlecell.broadinstitute.org/single_cell/study/SCP1289/impaired-local-intrinsic-immunity-to-sars-cov-2-infection-in-severe-covid-19
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
SS and CJP should be considered joint senior authors
Authorship All authors should have made substantial contributions to all of the following: (LD, SS, CJP) the conception and design of the study, acquisition of data, analysis and interpretation of data; (LD and AA) scRNA-seq data acquisition and analysis; (LD, SS, CJP) drafting the article; (LD, AA, SS, CJP) final approval of the version to be submitted.
Data Availability
All data produced in the present work are contained in the manuscript
Abbreviations
- BP
- biological process
- DEG
- differentially expressed genes
- GSEA
- Gene set enrichment analysis
- GO
- gene ontology
- miRNA
- microRNA
- scRNA-seq
- single-cell RNA sequencing
